Drug Trial Radar · NCT04435366
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
448
Actual
Start
Jun 22, 2020
Primary completion
Jul 25, 2022
Study completion Aug 22, 2023
Sponsor
- Lead sponsor
- IVERIC bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
Conditions
- Geographic Atrophy
- Macular Degeneration
Interventions
Avacincaptad PegolDrug
Avacincaptad Pegol Intravitreal Injection
ShamDrug
Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12Time frame: Baseline to month 12
- The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24Time frame: Baseline to month 24
Locations
205 sites in 20 countries. Site status is shown where the registry gives one.
Retina-Vitreous Associates Medical Group
Beverly Hills, California
Retinal Diagnostic Center
Campbell, California
Eye Medical Center of Fresno
Fresno, California
Retina Consultants of Orange County
Fullerton, California
University of California, San Diego
La Jolla, California
Jules Stein Eye Institute/David Geffen School of Medicine
Los Angeles, California
Northern California Retina Vitreous Associates
Mountain View, California
California Retina Consultants
Oxnard, California
Southern California Desert Retina Consultants
Palm Desert, California
Doheny Eye Center, UCLA
Pasadena, California
Retina Consultants of Southern California
Redlands, California
Retinal Consultants Medical Group, Inc.
Sacramento, California
Orange County Retinal Medical Group
Santa Ana, California
University of Colorado
Aurora, Colorado
Retina Consultants of Southern Colorado, P.C.
Colorado Springs, Colorado
Colorado Retina Associates
Lakewood, Colorado
Connecticut Eye Consultants, P.C.
Danbury, Connecticut
Retina Group of New England, PC
Waterford, Connecticut
Florida Eye Clinic
Altamonte Springs, Florida
Rand Eye Institute
Deerfield Beach, Florida
Retina Group of Florida
Fort Lauderdale, Florida
Retina Health Center
Fort Myers, Florida
National Ophthalmic Research Institute
Fort Myers, Florida
VitreoRetinal Associates, P.A.
Gainesville, Florida
Florida Eye Associates
Melbourne, Florida
University of Miami-Bascom Palmer Eye Institute
Miami, Florida
Retina Care Specialists
Palm Beach Gardens, Florida
Retina Specialty Institute
Pensacola, Florida
Retina Associates of Sarasota
Sarasota, Florida
Retina Vitreous Associates of Florida
St. Petersburg, Florida
East Florida Eye Institute
Stuart, Florida
Southern Vitreoretinal Associates, PL
Tallahassee, Florida
Center for Retina and Macula Disease
Winter Haven, Florida
Southeast Retina Center
Augusta, Georgia
Georgia Retina, P.C.
Marietta, Georgia
Retina Consultants of Hawaii, Inc
‘Aiea, Hawaii
University Retina and Macula Associates, PC
Lemont, Illinois
Illinois Eye Center
Peoria, Illinois
Midwest Eye Institute
Indianapolis, Indiana
Wolfe Eye Clinic
West Des Moines, Iowa
Showing 40 of 205 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.